Gregor E G Verhoef
Overview
Explore the profile of Gregor E G Verhoef including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, et al.
Lancet Haematol
. 2015 Dec;
2(2):e55-65.
PMID: 26687610
Background: Hodgkin's lymphoma is one of the most common lymphoid neoplasms in young adults, but the low abundance of neoplastic Hodgkin/Reed-Sternberg cells in the tumour hampers the elucidation of its...
2.
Thielen N, van der Holt B, Cornelissen J, Verhoef G, Gussinklo T, Biemond B, et al.
Eur J Cancer
. 2013 Jul;
49(15):3242-6.
PMID: 23876833
Background: Tyrosine kinase inhibitors treatment in responding chronic myeloid leukaemia (CML) patients is generally continued indefinitely. In this randomised phase II trial, we investigated whether CML patients in molecular response(4.5)...
3.
Vermaete N, Wolter P, Verhoef G, Kollen B, Kwakkel G, Schepers L, et al.
Cancer Epidemiol Biomarkers Prev
. 2013 May;
22(7):1173-84.
PMID: 23677574
Background: Physical activity has a protective effect on some types of cancer. The aim of the present meta-analysis was to explore the literature on the association between physical activity and...
4.
Thielen N, van der Holt B, Verhoef G, Ammerlaan R, Sonneveld P, Janssen J, et al.
Ann Hematol
. 2013 Apr;
92(8):1049-56.
PMID: 23572137
Despite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease still pose a considerable problem. In this multicenter,...
5.
Ossenkoppele G, Stussi G, Maertens J, van Montfort K, Biemond B, Breems D, et al.
Blood
. 2012 Oct;
120(24):4706-11.
PMID: 23047822
An urgent need for new treatment modalities is emerging in elderly patients with acute myeloid leukemia (AML). We hypothesized that targeting VEGF might furnish an effective treatment modality in this...
6.
Deenik W, Janssen J, van der Holt B, Verhoef G, Smit W, Kersten M, et al.
Haematologica
. 2009 Dec;
95(6):914-21.
PMID: 20015886
Background: In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with...
7.
Cornelissen J, van der Holt B, Verhoef G, Vant Veer M, van Oers M, Schouten H, et al.
Blood
. 2008 Nov;
113(6):1375-82.
PMID: 18988865
While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still disputed in adult patients with standard-risk ALL. We evaluated outcome...
8.
Deenik W, van der Holt B, Verhoef G, Smit W, Kersten M, Kluin-Nelemans H, et al.
Blood
. 2008 Jan;
111(5):2581-8.
PMID: 18172005
The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of...
9.
van den Heuvel-Eibrink M, van der Holt B, Burnett A, Knauf W, Fey M, Verhoef G, et al.
Ann Hematol
. 2007 Mar;
86(5):329-37.
PMID: 17340137
Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is associated with the expression of the multidrug resistance (MDR) proteins P-glycoprotein, encoded by the MDR1/ABCB1 gene, multidrug resistant-related protein (MRP/ABCC1),...
10.
Verdonck L, Notenboom A, de Jong D, MacKenzie M, Verhoef G, Kramer M, et al.
Blood
. 2006 Nov;
109(7):2759-66.
PMID: 17132720
Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an unresolved issue. We assessed whether dose intensifications with cyclophosphamide and...